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Available online 22 February 2011Heme oxygenase–carbon monoxide–cGMP (HO–CO–cGMP) pathway has been reported to be
involved inperipheral andspinalmodulationof inflammatorypain.However, the involvement
of this pathway in the modulation of acute painful stimulus in the absence of inflammation
remains unknown. Thus, we evaluated the involvement of the HO–CO–cGMP pathway in
nociception by means the of analgesia index (AI) in the tail flick test. Rats underwent surgery
for implantation of unilateral guide cannula directed toward the lateral ventricle and after the
recovery period (5–7 days) were subjected to the measures of baseline tail flick test. Animals
weredivided into groups to assess the effect of intracerebroventricular administration (i.c.v.) of
the following compounds: ZnDPBG (HO inhibitor) or vehicle (Na2CO3), heme-lysinate (substrate
overload) or vehicle (L-lysine), or the selective inhibitor of soluble guanilate cyclase ODQ or
vehicle (DMSO 1%) following the administration of heme-lysinate or vehicle. Heme overload
increased AI, indicating an antinociceptive role of the pathway. This responsewas attenuated
by i.c.v. pretreatmentwith the HO inhibitor ZnDPBG. In addition, this effect was dependent on
cGMP activity, since the pretreatment with ODQ blocked the increase in the AI. Because CO
produces most of its actions via cGMP, these data strongly imply that CO is the HO product
involved in the antinociceptive response. This modulation seems to be phasic rather than
tonic, since i.c.v. treatment with ZnDPBG or ODQ did not alter the AI. Therefore, we provide
evidence consistent with the notion that HO–CO–cGMP pathway plays a key phasic
antinociceptive role modulating noninflammatory acute pain.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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The pain sensation commonly refer to conscious experiences
associated with tissue injury or disease and are also used tontologia de Ribeirão Preto
A.L.- Panissi).
 the Elsevier OA license.describe discomfort related to other unpleasant feelings (Perl,
2007). The processing of nociceptive stimulus can be modu-
lated in forebrain, in midbrain, and in spinal cord through
mechanisms involving different neurotransmitters and, Universidade de São Paulo, 14040-904 Ribeirão Preto, SP, Brazil.
Fig. 1 – Effect of the HO inhibitor ZnDPBG on analgesia index
(AI) in the tail flick test. Effect of intracerebroventricular
injection of Na2CO3 (50 mmol/4 μL) or ZnDPBG (an HO
inhibitor, 50 nmol/4 μL or 200 nmol/4 μL) on AI in the tail
flick test. Values are means AI±SEM, number of animals in
parentheses.
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ide (CO) has been shown to play a role in peripheral and spinal
modulation of inflammatory pain (Nascimento and Branco,
2007), but no information is available as to its putative role in
acute pain modulation in the absence of inflammation.
CO has been recognized to act as a neurotransmitter or
neuromodulator in the nervous system (Mancuso et al., 2010).
Moreover, CO has been shown to be a mediator of endotoxin
fever in the central nervous system (Steiner et al., 1999; Steiner
and Branco, 2000). Most of CO's action has been reported to be
dependent on the activation of soluble guanylate cyclase (sGC)
activity and on subsequent increases the cellular levels of
cyclic GMP (Maines, 1993, 1997; Morita et al., 1995).
Endogenous CO arises from the cleavage of the heme
molecule yielding equilomar amounts of biliverdin, free iron
and CO, a process catalyzed by the enzyme heme oxygenase
(HO) (Maines, 1997). Three HO isoforms have been identified to
date: HO-1, HO-2, and HO-3, amongwhich the isoforms 1 and 2
are the best known (Ewing et al., 1992; Maines, 1997). Both
isoenzymes, one of them inducible (HO-1) and the other
constitutive (HO-2), have been found in various tissues,
including endothelial cells, smooth muscle and neural tissue
(Dawson and Snyder, 1994; Maines, 1997; Johnson et al., 1999).
Because the enzyme HO is widely distributed among the
central nervous system (CNS) and central nociceptive trans-
mission is an important step in pain perception and modu-
lation (Millan, 1999), we assessed the involvement of the HO–
CO–cGMP pathway in nociception by means the of analgesia
index (AI) in the tail flick test in rats. To this end, we
investigated whether microinjection of zinc deuteroporphyrin
2,4-bis glycol (ZnDPBG, an HO inhibitor), heme-lysinate
(substrate overload) or the selective inhibitor of soluble
guanylate cyclase (ODQ) into the lateral ventricle in different
groups of rats produces alterations on AI of the tail flick test.Fig. 2 – Antinociceptive effect of the HO substrate
heme-lysinate (Heme-lys) on analgesia index (AI) in the tail
flick test. Intracerebroventricular injection of L-lysine (L-lys),
heme-lysinate (150 nmol/4 μL, 300 nmol/4 μL or 600 nmol/
4 μL) or ZnDPBG (200 nmol/4 μL) followed 15 min after by
Heme-lys (150 nmol/4 μL) on AI in the tail flick test. Values
are means AI±SEM, number of animals in parentheses.
Intracerebroventricular injection of heme-lysinate in
different doses elicited a significant (p<0.05) increase in AI
whereas no change was observed after i.c.v. administration
of L-lysine. Pretreatment with ZnDPBG attenuated (p<0.05)
the antinociceptive effect evoked by heme-lysinate.2. Results
The results of the present study initially showed that the i.c.v.
administration of ZnDPBG (an HO inhibitor, at the doses
50 nmol/4 μL or 200 nmol/4 μL) did not alter the analgesia
index (AI) in the tail flick test when compared with control
period [F(8,71)=0.68, p=0.706 to ZnDPBG 50 nmol and F(8,62)=0.56,
p=0.804 to ZnDPBG 200 nmol, one-way ANOVA] or when
compared [F(8,206)=0.403, p=0.941, two-way ANOVA] with the
group that received the vehicle (Na2CO3, 50mmol/4 μL), evalu-
ated for 120 minat intervalsof 15min (Fig. 1).On theotherhand,
the i.c.v.microinjectionof heme-lysinate (which induces theHO
pathway) at the doses 150 nmol/4 μL, 300 nmol/4 μL or
600 nmol/4 μL promoted an increase in the AI evaluated in the
tail flick test in rats when compared with the respective control
period [F(8,62)=4.465, p<0.001, F(8,71)=2.294, p<0.05, F(8,62)=25.248,
p<0.001 respectively to heme-lysinate 150 nmol, 300 nmol
and 600 nmol, one-way ANOVA] with all experimental time
(p<0.05, Tukey test, Fig. 2). Furthermore, the statistical analysis
showedadifference inAIamongthegroups that received the i.c.
v. administration of heme-lysinate, at different doses, and the
group that received the L-lysine-vehicle solution [F(8,251)=2.272,
p=0.001, two-way ANOVA] during all experimental time
(p<0.05, Newman–Keuls test, Fig. 2). This effect was attenuatedby treatment with ZnDPBG (200 nmol) before i.c.v. administra-
tion of heme-lysinate (150 nmol) when compared with the
group that received heme-lysinate at the same dose [F(16,170)=
4.589, p<0.001, two-way ANOVA] during 15–60 min intervals
(p<0.05, Newman–Keuls test, Fig. 2).
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plus heme-lysinate (300 nmol/4 μL) promoted an increase in
the AI of the tail flick test when compared with the control
period [F(8,44)=3.682, p=0.003, one-way ANOVA] during 15–
45 min intervals (p<0.05, Newman–Keuls test, Fig. 3A). This
effect was prevented by i.c.v. treatment 30 min before the
heme-lysinate (300 nmol) with the sGC inhibitor ODQ
(5.2 nmol/4 μL) [F(1,125) =41.48, p<0.001, two-way ANOVA]
until 90 min of the experiment (p<0.05, Newman-Keuls
test, Fig. 3A).
Fig. 3B shows the effect of the i.c.v. injection of sGC
inhibitor ODQ or vehicle (DMSO 1%) 30 min before theFig. 3 – Inhibition of the antinociceptive effect of the HO
substrate heme-lysinate (Heme-lys) on analgesia index (AI)
in the tail flick test. A: Intracerebroventricular injection of
soluble guanylate cyclase inhibitor (ODQ, 5.2 nmol/4 μL) or
vehicle (DMSO 1 %) followed 30 min later by heme-lysinate
(300 nmol/4 μL) on AI in the tail flick test. Values are means
AI±SEM, number of animals in parentheses. Pretreatment
with ODQ prevent (p<0.05) the antinociceptive effect evoked
by heme-lysinate. B: Intracerebroventricular injection of the
ODQ (5.2 nmol/4 μL) or vehicle (DMSO 1%) followed 30 min
later by L-lysine on AI in the tail flick test. Values are means
AI±SEM, number of animals in parentheses.administration of the vehicle of heme-lysinate, L-lysine,
which served as control. Statistical analysis demonstrated
that the AI in these groups did not differ from the respective AI
in the control period [F(7,71)=0.860, p=0.555; F(7,71)=1.287,
p=0.269 one-way ANOVA, ODQ+L-lysine and DMSO+L-lysine
respectively]. The groups ODQ+L-lysine and DMSO+L-lysine
groups did not differ throughout the experiment [F(8,142)=
1.156, p=0.331, two-way ANOVA, Fig. 3B].3. Discussion
The present data are consistent with the notion that the HO–
CO–cGMP pathway modulates nociception in the brain,
playing an antinociceptive role. This conclusion is based on
the fact that i.c.v. administration of the HO pathway-inducer
heme-lysinate increased AI and that this effect could be
attenuated by the i.c.v. pretreatment with ZnDPBG or with
sGC inhibitor, ODQ. Moreover, CO seems to be the HO product
responsible for this effect because it acts through a cGMP-
dependent way (Maines, 1997; Nascimento and Branco, 2007).
We also demonstrated that the i.c.v. microinjection of
ZnDPBG (a competitive inhibitor of the HO) did not cause
changes in the AI, indicating that HO–CO–cGMP pathway
exhibits phasic but not tonic characteristics in the nocicep-
tive modulation of acute painful stimuli in the absence of
inflammation.
Since the beginning of the 1990s, a growing body of
evidence has confirmed the physiological actions of the
gaseous compound CO, which has been shown to be a
vasoactive substance and to act as a neurotransmitter/
neuromodulator (Dawson and Snyder, 1994; Johnson et al.,
1999). HO is the enzyme responsible for CO biosynthesis and
has been found to be expressed in the CNS of several species,
including rats (Alam and Den, 1992; Ewing and Maines, 1992)
and humans (Maines et al., 1996). Accordingly, evidence has
accumulated that the HO–CO pathway plays an important role
in the control of arterial blood pressure (Johnson et al., 1999),
in themechanical hypernociception (Steiner and Branco, 2001)
and in the formalin test (Nascimento and Branco, 2007).
The HO enzyme inhibitor ZnDPBG prevents cleavage of the
heme molecule and thus the production of endogenous
biliverdin, free iron and carbon monoxide (Maines, 1997).
Direct intrathecal injection of ZnDPBG produced hypernoci-
ception, which was characterized by an increased flinching
nociceptive response to the formalin test (Nascimento and
Branco, 2007, 2008) or mechanical hypersensitivity (Steiner
and Branco, 2001). In addition, recent information (Nasci-
mento and Branco, 2009) shows that administration of doses
without any effect on ZnDPBG, when given alone, may
promote the same hypernociceptive effect when administered
intrathecally and locally. This suggests that the enzyme heme
oxygenasemodulates the inflammatory nociceptive response.
These findings show that the activation of the HO system in
the spinal cord can modulate the nociception in peripheral
tissues (Nascimento and Branco, 2009). The present study
adds to this scenario, demonstrating that heme overload
using heme-lysinate has an antinociceptive effect in the
absence of inflammation, evidenced by the increase in the
AI in the tail flick test. Similar findings have been observed
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Branco 2007) or given intrathecally (Nascimento and Branco
2008), indicating that HO pathway plays an antinociceptive
role at peripheral nervous system, spinal cord and brain.
Furthermore, the HO pathway may involve not only the
modulation of inflammatory mediator release or activity but
also changes in nociceptors, fiber excitability and spinal
sensitization.
The modulation of nociception by the activity of the HO–
CO–cGMP pathway is due to increased intracellular cGMP
levels because intrathecal treatment with heme-lysinate is
blocked by pre-administration of methylene blue (inhibitor of
sGC) at the same site. In addition, evidence shows that cGMP is
capable of tonically modulating nociception associated with
the inflammatory response because the administration of
methylene blue (150 μg) caused hypernociception in the
formalin test (Nascimento and Branco, 2008, 2009).
Our data also show that the administration of sGC inhibitor
(ODQ) prior to administration of heme-lysinate blocked the
antinociception observed in the tail flick test in rats. These
results support the hypothesis that the antinociception
obtained in our experiments is mediated by CO and related to
increase of intracellular cGMP. Within this context, several
studies have demonstrated that modulation of nociception
can occur by altering the activity of intracellular cGMP (Meller
and Gebhart, 1993; Duarte and Ferreira, 1992; Nascimento and
Branco, 2007, 2008). However, the change in intracellular
levels of cGMP can result in pro- or antinociceptive effects,
depending on the magnitude of the increase in cGMP as well
as whether the drug is administered locally (in the peripheral
nervous system or spinal cord). Thus, studies have shown
that increased cGMP activity in the spinal cord inhibits the
activity of spinal neurons, mainly nociceptive neurons of the
dorsal horn in the spinal cord (Manjarrez et al., 2001, Pehl and
Schmid, 1997; Hoheisel et al., 2000). In contrast, Hoheisel et al.
(2005) demonstrated that the supraspinal increase in the
levels of cGMPpromoted excitement in neurons located in the
dorsal horn of the spinal cord, suggesting a probable pro-
nociceptive effect. In our experiments, the increase of cGMP
was promoted by activation of theHO–CO–cGMPpathway and
slight increases in CO activated sGC (Burstyn et al., 1995).
Therefore supraspinal cGMP may have a dual effect; high
levels of cGMP may have a pro-nociceptive effect or increase
the activity of spinal nociceptive neurons (Hoheisel et al.,
2005). In contrast, lower-magnitude changes in supraspinal
cGMP induce antinociceptive effects, as evidenced by the
increase in AI after administration of heme-lysinate, which
was blocked by the pretreatment with ODQ (inhibitor of sGC).
It is possible that themodulation of nociception by increasing
supraspinal cGMPoccurs in regions that control the activity of
the descending tracts of spinal neurons (Hoheisel et al., 2005).
Assuming that i.c.v. injection can affect all the cerebral
ventricles (Yu et al., 1991), localization of the supraspinal
effect remains to be determined. Areas known to inhibit the
activation nociceptive descending neurons, including the
periaqueductal gray matter, amygdala and thalamus, may
also be involved (Fields and Basbaum, 1999; Millan, 2002). The
most common isoforms of the heme oxygenase enzyme, HO-
1 and HO-2, have wide distribution in the central nervous
system (Ewing and Maines, 1992). Among the areas thatexpress HO, intense immunoreactivity can be observed in the
hippocampal complex, including pyramidal neurons in CA1–
CA3, neurons of the granular layer and some neurons in the
dentate gyrus (Ewing et al., 1993, Maines et al., 1996). Recent
work (Shih et al., 2008) using functional mapping techniques
showed that the nociception induced by administration of
formalin 5% intra-foot wide in rats promoted activation of
different brain areas, including hippocampus. In fact, the
involvement of the hippocampus in nociceptive modulation
is widely described (Lico et al., 1974, Khanna, 2007) and
suggests that this structure is involved in the affective–
motivational component of pain (Lico et al., 1974, Henke,
1982). In addition, studies have correlated the activity of cGMP
with functions performed by the hippocampal areas (Bon and
Garthwaite, 2003, Hopper and Garthwaite, 2006). Hippocam-
pal areas have been shown to express high levels of HO
isoenzymes, and CO has been suggested to be the main sig-
naling molecule for sGC in this structure (Maines, 1997).
Moreover, the activity of cGMP in the hippocampus may be
related to the activation of NMDA receptors (Garthwaite et al.,
1995), and the glutamatergic NMDA-type mediates different
physiological functions, including nociception (Dubner, 2004,
Meller et al., 1996, Morgan et al., 2009).
Thus, our data show that activation of the HO–CO–cGMP
pathway promotes antinociception, as assessed by tail flick
test in rats. We speculate that the hippocampus is one of the
areas involved in nociceptive modulation induced by in-
creased cGMP formation, induced by CO carried on the heme
molecule.4. Experimental procedures
4.1. Animals
Experiments were performed on male Wistar rats weighing
250–300 g obtained from the animal facility of the University of
Sao Paulo, Ribeirao Preto, Brazil. The animals were housed in a
room with controlled temperature (24±1 °C) and a 12-h light/
dark cycle (lights on at 06:00 h) with food and water ad libitum.
All experimental procedureswere approved by the Animal Use
and Ethics Committee of the Ribeirao Preto, University of Sao
Paulo (Process no. 07.1.997.53.4).
4.2. Surgery
During all surgical procedures, animals were submitted to
anesthesia with ketamine and xylazine (75 and 10 mg/kg,
respectively, administered intramuscularly). Animals desig-
nated for experiments involving intracerebroventricular (i.c.v.)
injectionswere fixed in a stereotaxic frame and had a stainless
steel guide cannula introduced into the right lateral cerebral
ventricle (coordinates: 1.0 mm posterior, 1.6 mm lateral to
midline and 3.2–3.7 mm ventral to the skull surface) (Paxinos
and Watson, 1998). Displacement of the meniscus in a water
manometer ensured correct positioning of the cannula in the
lateral ventricle. The cannulas were attached to the bone with
stainless steel screws and acrylic cement. A tight-fitting stylet
was kept inside the guide cannula to prevent occlusion. After
surgery, animals were treated with Pentabiotic (Fort Dodge,
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1 week after surgery.
4.3. Drugs and microinjection procedure
The non-selective HO inhibitor zinc deuteroporphyrin 2,4-bis
glycol (ZnDPBG, 50 nmol/4 μL and 200 nmol/4 μL) and hemin
were obtained from Porphyrin Products (Logan, UT, USA).
ZnDPBG was dissolved in 50 mmol/L of Na2CO3 and stored in
the dark. Hemin was used to prepare heme-lysinate (at the
doses 150 nmol/4 μL, 300 nmol/4 μL and 600 nmol/4 μL), a HO–
CO–cGMP pathway inducer, as previously described (Steiner
et al., 2001). Heme-free preparations were used as amino acid
(L-lysine) vehicle control solutions. The vehicle of heme-
lysinate consisted of L-lysine (14.2 μmol/mL), ethanol (5%),
propylene glycol (40%) and sterile water (55%). The sGC
inhibitor 1H-[1,2,4] oxadiazolo [4,3-a] quinoxaline-1-one
(ODQ, 5.4 nmol/4 μL) was purchased from Tocris Cookson (St.
Louis, MO) and dissolved in a vehicle consisting of 1% DMSO in
pyrogen-free sterile saline. The doses employedwere based on
previous studies [Nascimento and Branco, 2008; Ravanelli
et al., 2006; Steiner and Branco, 2001; Steiner et al., 2001 and
2003].
For the i.c.v. injections, a 10-μL Hamilton syringe con-
nected to a dental injection needle by a PE-10 catheter was
used. At the time of drug administration, the stylet was re-
placed with the injection needle and 4 μL of the studied drug
were infused over a period of 1 min (Steiner et al., 2003; Paro
et al., 2002; Ravanelli et al., 2006). To prevent reflux, theneedle
was kept inside the guide cannula for 40 s after the end of the
infusion.
4.4. Tail flick test
Nociceptionwas assessedwith a tail flick apparatus. Rats were
restrained manually and placed on the apparatus, which
measured time in seconds (latency) that the animal took to
issue the reflection, that is, remove the tail from the noxious
thermal stimulus. A cutoff time of 6 s was used to prevent
tissue damage. Before treatment was initiated, the response
latency in seconds for each animal was determined three
consecutive times at random intervals of 1–3 min. After
measurement of basal latency, animals were divided into
different experimental groups and were then subjected to tail
flick test after various experimental treatments at intervals of
15 min until the maximum time of 120 min.
4.5. Experimental protocols
4.5.1. Determination of the effect of intracerebroventricular
ZnDPBG in acute nociception, as assessed by the tail flick test in
rats
Rats previously cannulated in the lateral cerebral ventricle
were treated after surgery with Pentabiotic. The experiments
were initiated 1 week after surgery. The animals were evalu-
ated in the tail flick test to determine the baseline and then
microinjected i.c.v. with the HO inhibitor ZnDPBG (50 nmol/
4 μL or 200 nmol/4 μL) or with the vehicle (Na2CO3/50 mmol/
4 μL). The rats were then submitted 15 min later to the
nociceptive test at 15-min intervals until 120 min.4.5.2. Determination of the effect of intracerebroventricular
heme-lysinate in acute nociception in rats, as assessed in the tail
flick test
Rats previously cannulated in the lateral cerebral ventricle
after surgery were treated with Pentabiotic. The experiments
were initiated 1 week after surgery. The animals were
evaluated by the tail flick test to determine the baseline and
then microinjected i.c.v. with heme-lysinate (150 nmol/4 μL,
300 nmol/4 μL and 600 nmol/4 μL) or the L-lysine vehicle
solution (4 μL). The rats were then submitted 15 min later to
the nociceptive test at 15-min intervals until 120 min.
In another experimental group, the animals were evaluat-
ed by the tail flick test to determine the baseline and then
microinjected i.c.v. with ZnDPBG (200 nmol/ 4 μL) and 15 min
later, heme-lysinate (150 nmol/4 μL) was injected into the
lateral ventricle. The rats were then submitted 15 min later to
the nociceptive test at 15-min intervals until 120 min.
4.5.3. Determination of the effect of the intracerebroventricular
sGC inhibitor ODQ in acute nociception in rats, as assessed by the
tail flick test
Rats previously cannulated in the lateral cerebral ventricle
were treated with Pentabiotic. The experiments were initiated
1 week after surgery. The animals were evaluated in the tail
flick test to determine the baseline and thenmicroinjected i.c.
v. with ODQ (5.2 nmol/4 μL) or with DMSO 1% vehicle (4 μL)
30 min before i.c.v. administration of heme-lysinate
(300 nmol/4 μL) or L-lysine vehicle solution (4 μL). Fifteen
minutes later, rats were submitted to the nociceptive test
again at intervals of fifteenminutes until one hundred twenty
minutes.
4.6. Histology
At the end of the experiments, rats were anesthetized with
hydrate of chloral (10%, 0.35 mL/100 mg body weight, i.p.) and
transcardially perfused with saline (NaCl, 0.9%), followed by
10% formalin. The brains were then removed and fixed in 10%
formalin. The material was then submitted to routine
histological processing and sections were observed under a
microscope according to the Paxinos and Watson Atlas (1998).
4.7. Statistical analysis
Each tail flick latency was normalized using an index of
antinociception tail flick test (AI) according to the following
formula: tail flick test− tail flick control/cutoff time− tail flick
control, where tail flick control is the average of 3 baselines of
tail-flick latencies. AI represents the antinociception index tail
flick test; latency is the time that the animal takes to issue a
response after the experimental treatment; baseline is the
period of latency in the control; 6 s were necessary to stop the
noxious thermal stimulus.
The data are reported as the mean AI±SEM (standard error
of mean) and were analyzed by repeated measures multivar-
iate analysis of variance, with the variables being time
(repeated factor) and treatment (independent factor), followed
by one-way ANOVA and Tukey's test. For the different
experimental groups, the values of AI were compared with
treatment vs. time using a two-way ANOVA for repeated
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considered statistically significant when p<0.05.Acknowledgments
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